Only in Titles

Search results for: ASK1(Phospho-Ser966) Antibody

paperclip

Error loading info... Pleas try again later.
paperclip

#33971559   2021/05/04 To Up

Macrophage-preferable delivery of the leucine-rich repeat domain of NLRX1 ameliorates lethal sepsis by regulating NF-κB and inflammasome signaling activation.

Sepsis is an acute systemic inflammatory disease triggered by bacterial infection leading organ dysfunctions that macrophages are responsible for major triggering of systemic inflammation. Treatment options are limited to antibiotics and drugs to manage the symptoms of sepsis, but there are currently no molecular-targeted therapies. Here, we identified a novel macrophage-preferable delivery peptide, C10, which we conjugated to truncated domains of NLRX1 (leucine-rich repeat region (LRR), and nucleotide binding domain (NBD)) to obtain C10-LRR and C10-NBD. Leucine rich amino acid of C10 enables macrophage preferable moieties that efficiently deliver a cargo protein into macrophages in vitro and in vivo. C10-LRR but not C10-NBD significantly improved survival in an LPS-mediated lethal endotoxemia sepsis model. C10-LRR efficiently inhibited IL-6 production in peritoneal macrophages via prevention of IκB degradation and p65 phosphorylation. In addition, C10-LRR negatively regulated IL-1β production by preventing caspase-1 activation with a sustained mitochondrial MAVS level. Finally, co-treatment with anti-TNFα antibody and C10-LRR had a synergistic effect in an LPS-induced sepsis model. Collectively, these findings indicate that C10-LRR could be an effective therapeutic agent to treat systemic inflammation in sepsis by regulating both NF-κB and inflammasome signaling activation.
Ja-Hyun Koo, Sang-Hun Kim, Soung-Hoo Jeon, Min-Jong Kang, Je-Min Choi

2602 related Products with: Macrophage-preferable delivery of the leucine-rich repeat domain of NLRX1 ameliorates lethal sepsis by regulating NF-κB and inflammasome signaling activation.

100ul50 ug 100ug 5 G100ug0.05 mg100ug100ug 100ul100ug1.5x10(6) cells100μg

Related Pathways

paperclip

#33971536   2021/04/06 To Up

Time-resolved fluorescent lateral flow strip for easy and rapid quality control of edible oil.

Gutter oil is strictly prohibited from being reprocessed back to the catering and food industry. Extensive attention has been paid to rapid screening of gutter oil to guarantee the safety of edible oil. Capsaicin, a special component of condiments, has been adopted as the marker of gutter oil. The time-resolved fluorescent microspheres are utilized for labeling of antibody to capsaicin, which are further applied for the construction of fluorescent lateral-flow-strip (LFS). By simple extraction of capsaicin with ethanol (or liquor) from the edible oil, the capsaicin can be rapid determined with the fluorescent LFS in less than 10 min. As low as 20 ng/mL capsaicin can be visually judged and 2.3 ng/mL is achieved as the detection limit by ImageJ analysis. The illegal gutter oil is also well screened with this time-resolved LFS. This method can be a useful candidate for routine quality monitoring of edible oil and a powerful tool for self-inspection at home.
Qian Wu, Li Yao, Panzhu Qin, Jianguo Xu, Xun Sun, Bangben Yao, Fei Ren, Wei Chen

2084 related Products with: Time-resolved fluorescent lateral flow strip for easy and rapid quality control of edible oil.

1 kit1One 96-Well Strip Micropl100 mgOne 96-Well Strip Micropl96 wells

Related Pathways

paperclip

#33971523   2021/05/07 To Up

Evaluation of immunogenicity and protection mediated by Lawsonia intracellularis subunit vaccines.

Lawsonia intracellularis is an economically important bacterium that causes ileitis in pigs. Current vaccines for L. intracellularis do not allow for differentiation between infected and vaccinated animals (DIVA), which is beneficial for disease tracking and surveillance. Previously, we identified five putative surface L. intracellularis proteins that were targeted by antibodies from pigs infected with L. intracellularis which could serve as antigens in a subunit vaccine. We conducted two trials to determine whether these antigens were immunogenic and provided protection against infectious challenge and whether truncated glycoprotein D could be used as a DIVA antigen. For Trial 1, 5 week-old piglets were administered intramuscular monovalent vaccines comprised of a recombinant (r) flagella subunit protein (rFliC,) and DIVA antigen (truncated glycoprotein D (TgD), a herpes virus antigen) both formulated with a combination adjuvant consisting of polyinosinic:polycytidylic acid(poly I:C), host defense peptide 1002 and polyphosphazene, referred to as Triple Adjuvant (TriAdj). Relative to control animals, animals vaccinated with rFliC and rTgD had significantly elevated antigen-specific humoral immunity in sera suggesting that rFliC and TgD are immunogenic. Control animals had negligible anti-TgD titres suggesting that TgD may be a suitable DIVA antigen for pigs. For Trial 2, piglets were immunized with a trivalent vaccine (FOG vaccine consisting of rFLiC, rOppA protein (a ABC Type dipeptide transport system) and rGroEL (a stress response protein)) and a divalent vaccine (CM vaccine consisting of rClpP (an ATP-dependent Clp protease proteolytic subunit) and rMetK (a S-adenosyl methionine synthase)) formulated with Emulsigen®. Relative to the control pigs, pigs immunized with the FOG vaccine produced robust and significantly higher serum IgG antibodies against rFliC and rGroEL, and significantly higher anti-FliC and anti-GroEL IgA antibodies in jejunal (GroEL only) and ileal intestinal mucosa. Pigs immunized with CM vaccine produced significantly higher serum antibodies against rClpP and rMetK and significantly higher anti-rClpP IgA antibodies in the ileum relative to the control pigs. Quantitative polymerase chain reaction (qPCR) analysis showed that 18 days after challenge with infectious L. intracellularis, challenged/control pigs and pigs that received the CM vaccine, but not the pigs vaccinated with the FOG vaccine, shed significantly more bacteria in feces than the unchallenged controls pigs. These data suggest that the FOG vaccinated pigs showed limited protection. While promising, more work is needed to enhance the efficiency of the intramuscular vaccine to show significant disease protection.
Kezia R Fourie, Pooja Choudhary, Siew Hon Ng, Milan Obradovic, Robert Brownlie, Sanjeev K Anand, Heather L Wilson

1856 related Products with: Evaluation of immunogenicity and protection mediated by Lawsonia intracellularis subunit vaccines.

1000 tests100ul1 ml250ul200ul1 mg0.05 mg25 mg100ug 100ul1000 2.5 mg

Related Pathways

paperclip

#33971510   2021/05/07 To Up

Tatibody, a recombinant antibody with higher internalization potency.

Using antibody drug conjugates (ADC) which can exclusively bind to their target cells and upon internalization release their toxic agent, is one of the most effective methods for killing tumor cells. Therefore, increasing the internalization rate is an important factor for tumor treatment in this case. The aim of the present study was to develop a new variant of pertuzumab (an anti-ErbB2 humanized antibody) with higher internalization rate that can be a good candidate for the production of ADC. To this end, the Human Immunodeficiency Virus TAT Protein Transduction Domain (TAT-PTD) was replaced into the structure of the pertuzumab. At first, the best site in antibody heavy chain constant region for the replacement of TAT-PTD was predicted through computational methods. Then, the resulting recombinant antibody, of which TAT-PTD was located at amino acid position 130-140 and named Tatibody, was produced in CHO-S cell line. Finally, its physicochemical properties and biological activities were evaluated and compared with pertuzumab. Results showed that the binding ability of Tatibody to the ErbB2 receptor is similar to that of pertuzumab, but its internalization potency is 3.6 fold higher and can be used as a good candidate for ADC construction.
Amin Ramezani, Amir Asgari, Elina Kaviani, Ahmad Hosseini, Abbas Ghaderi

1021 related Products with: Tatibody, a recombinant antibody with higher internalization potency.

1mg1021 mg500 50 100 100ug100ug100ug Lyophilized32-50 Sample Kit100ug

Related Pathways

paperclip

Error loading info... Pleas try again later.
paperclip

#33971403   2021/05/07 To Up

Novel Japanese encephalitis virus NS1-based vaccine: Truncated NS1 fused with E. coli heat labile enterotoxin B subunit.

Current vaccines against Japanese encephalitis virus (JEV) of flaviviruses have some disadvantages, such as the risk of virulent reversion. Non-structural protein NS1 is conserved among flaviviruses and confers immune protection without the risk of antibody-dependent enhancement (ADE). Therefore, NS1 has become a promising vaccine candidate against flaviviruses.
Jiawu Wan, Ting Wang, Jing Xu, Tao Ouyang, Qianruo Wang, Yanni Zhang, Shiqi Weng, Yihan Li, Yu Wang, Xiu Xin, Xiaoling Wang, Sha Li, Lingbao Kong

1526 related Products with: Novel Japanese encephalitis virus NS1-based vaccine: Truncated NS1 fused with E. coli heat labile enterotoxin B subunit.

1 mg1 mg500 100 1000 1 mg1000 100 µg500 100 1000 1000

Related Pathways

paperclip

#33971346   2021/05/07 To Up

CCR6-CCL20 axis as a therapeutic target for autoimmune diseases.

Chemokine receptor CCR6 is expressed on various cells such as B cells, immature dendritic cells, innate lymphoid cells (ILCs), regulatory CD4 T cells, and Th17 cells. CCL20 is the only known high-affinity ligand that binds to CCR6 and drives CCR6 cells' migration in tissues. CCL20 is mainly produced by epithelial cells, and its expression is increased by several folds under inflammatory conditions. Genome-wide association studies (GWAS) in patients with inflammatory bowel disease (IBD), psoriasis (PS), rheumatoid arthritis (RA), and multiple sclerosis (MS) showed a very strong correlation between the expression of CCR6 and disease severity. It has been shown that disruption of CCR6-CCL20 interaction by using antibodies or antagonists prevents the migration of CCR6 expressing immune cells at the site of inflammation and reduces the severity of the disease. This review discussed the importance of the CCR6-CCL20 axis in IBD, PS, RA, and MS, and recent advances in targeting the CCR6-CCL20 in controlling these autoimmune diseases.
Heikrujam Thoihen Meitei, Nandadeep Jadhav, Girdhari Lal

2136 related Products with: CCR6-CCL20 axis as a therapeutic target for autoimmune diseases.

100 tests0.25 mg1 ml540 tests25 µg0.1ml (1mg/ml)250 ml100 TESTS0.2 mg

Related Pathways

paperclip

#33971320   2021/05/07 To Up

Activation of CD137 signaling promotes macrophage apoptosis dependent on p38 MAPK pathway-mediated mitochondrial fission.

CD137 signaling is an essential factor in cell fate and atherosclerosis. An increase in the number of apoptotic macrophages accelerates atherosclerotic development involving mitochondrial dynamics.However, the role of CD137 signaling in macrophage apoptosis and changes in mitochondria has not been demonstrated clearly.
Yu Xu, Yue Zhang, Yao Xu, Guangyao Zang, Bo Li, Hao Xia, Wei Yuan

2227 related Products with: Activation of CD137 signaling promotes macrophage apoptosis dependent on p38 MAPK pathway-mediated mitochondrial fission.

2 Pieces/Box100ug2 Pieces/Box100ug2 Pieces/Box100ug Lyophilized2 Pieces/Box100ugInhibitors2 Pieces/Box100ug100ug Lyophilized

Related Pathways

paperclip

#33971319   2021/05/07 To Up

COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors.

Clinical management protocols for COVID-19 are evolving rapidly as more information about the epidemiology and pathophysiological changes in COVID-19 becomes available. However, no definite treatment of COVID-19 pandemic has been found till date. The COVID-19 convalescent plasma (CCP) therapy has emerged as an important investigational therapy in the management of COVID-19 patients. Additionally, the regulatory agencies, in particular, the Indian blood transfusion council must release some interim recommendations for the blood centres on the CCP blood donor eligibility criteria after COVID-19 vaccination. More clinical trials are needed to know the efficacy of the CCP harvested from COVID-19 recovered individuals who have been vaccinated against the COVID-19 recovered individuals who are not vaccinated to understand the vaccine impact on the IgG titre of anti-SARS-Cov-2 antibodies.
Naveen Bansal, Manish Raturi, Yashik Bansal

1564 related Products with: COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors.

min 2 cartons100.00 ul 100 G1200 units1

Related Pathways